Multiple studies suggest a possible connection between poor clinical prognosis in patients with high CD276 expression on tumor cells and lower tumor infiltrated lymphocytes such as CD8+ T cells, which implies an immune-modulatory role of CD27619–22. This evidence concerns the gene CD276 and neoplasm.